PolyPid Updates On SHIELD II Trial Amidst KOL Insights On Surgical Site Infection Prevention
PolyPid Updates On SHIELD II Trial Amidst KOL Insights On Surgical Site Infection Prevention
在KOL洞察手術部位感染預防方面，Polypid對SHIELD II試驗進行更新
- After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels
- Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs
- Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II
- Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025
- 在 COVID 期間，手術部位感染（SSI）發病率降低了，但現在上升，預示着回到 COVID 之前的水平。
- 已知的程序和患者風險因素顯著增加了 SSIs 的風險並影響了支付者的費用。
- SHIELD II 計劃招募總計 600 個受試者中的約 250 名患者。
- 大約有 400 名患者完成了 30 天的隨訪後，將進行解盲的中期分析。到 2025 年第一季度將公佈頭條結果。2025 年第一季度公佈結果。